Kymera Therapeutics Inc (KYMR)

$32.24

+0.68

(+2.15%)▲

Live

Insights on Kymera Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 47.88M → 10.28M (in $), with an average decrease of 78.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -14.36M → -48.55M (in $), with an average decrease of 238.0% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 72.6% return, outperforming this stock by 55.9%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 235.1% return, outperforming this stock by 268.9%

Performance

  • $31.15
    $32.58
    $32.24
    downward going graph

    3.38%

    Downside

    Day's Volatility :4.39%

    Upside

    1.04%

    downward going graph
  • $9.60
    $45.31
    $32.24
    downward going graph

    70.22%

    Downside

    52 Weeks Volatility :78.81%

    Upside

    28.85%

    downward going graph

Returns

PeriodKymera Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-25.92%
-1.0%
0.0%
6 Months
48.38%
9.6%
0.0%
1 Year
20.05%
11.0%
0.0%
3 Years
-33.84%
18.5%
-22.6%

Highlights

Market Capitalization
2.0B
Book Value
$11.59
Earnings Per Share (EPS)
-2.51
Wall Street Target Price
51.07
Profit Margin
-194.67%
Operating Margin TTM
-514.3%
Return On Assets TTM
-14.6%
Return On Equity TTM
-26.35%
Revenue TTM
79.4M
Revenue Per Share TTM
1.29
Quarterly Revenue Growth YOY
8.7%
Gross Profit TTM
-117.4M
EBITDA
-170.5M
Diluted Eps TTM
-2.51
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.84
EPS Estimate Next Year
-3.09
EPS Estimate Current Quarter
-0.73
EPS Estimate Next Quarter
-0.77

Analyst Recommendation

Buy
    69%Buy
    30%Hold
    0
    0%Sell
Based on 23 Wall street analysts offering stock ratings for Kymera Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 23 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
15
15
Hold
7
7
6
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 58.41%

Current $32.24
Target $51.07

Technicals Summary

Sell

Neutral

Buy

Kymera Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Kymera Therapeutics Inc
Kymera Therapeutics Inc
-17.6%
48.38%
20.05%
-33.84%
-5.11%
Moderna, Inc.
Moderna, Inc.
21.03%
85.08%
14.68%
-28.27%
659.22%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.22%
20.18%
31.88%
93.3%
227.58%
Novo Nordisk A/s
Novo Nordisk A/s
8.85%
34.38%
71.83%
235.07%
463.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
16.81%
34.1%
40.6%
123.97%
174.53%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Kymera Therapeutics Inc
Kymera Therapeutics Inc
NA
NA
NA
-2.84
-0.26
-0.15
NA
11.59
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.14
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.89
28.89
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.97
46.97
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.59
29.59
0.53
17.08
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Kymera Therapeutics Inc
Kymera Therapeutics Inc
Buy
$2.0B
-5.11%
NA
-194.67%
Moderna, Inc.
Moderna, Inc.
Buy
$54.6B
659.22%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.0B
227.58%
28.89
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$602.6B
463.44%
46.97
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$117.5B
174.53%
29.59
39.46%

Institutional Holdings

  • Baker Bros Advisors LP

    9.77%

  • T. Rowe Price Associates, Inc.

    8.70%

  • Wellington Management Company LLP

    7.85%

  • Vanguard Group Inc

    6.52%

  • venBio Select Advisor LLC

    6.15%

  • BlackRock Inc

    5.81%

Company Information

kymera therapeutics is pioneering a transformative new approach to treating previously untreatable diseases. we are advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins. powered by a proprietary predictive modeling capability and a game-changing integrated degradation platform with a novel small molecule modality, our company is committed to accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. learn more at kymeratx.com.

Organization
Kymera Therapeutics Inc
Employees
186
CEO
Dr. Bruce L. Booth DPHIL, Ph.D.
Industry
Health Technology

Discover More

FAQs